Meta-analysis of neurocognition in young psychosis patients with current cannabis use
Introduction
Cannabis remains the most prevalent illicit drug used by individuals with schizophrenia-spectrum disorders (Koskinen et al., 2010, Smucny et al., 2014, Amminger et al., 2006), and current chronic use has been shown to significantly worsen positive psychotic symptoms in patients (Talamo et al., 2006, Dubertret et al., 2006). Counterintuitively, meta-analyses and systematic reviews suggest that cognitive functioning in chronic schizophrenia patients with a history of, but not current, cannabis use (CANN±) is superior to that of their peers who have never used cannabis (CANN-) (Yücel et al., 2012, Løberg and Hugdahl, 2009). This suggests that there may be different phenotypes among older individuals with chronic psychotic disorders. However, relatively little is known about the cognitive profiles in the context of cannabis use in younger individuals with early psychosis. Prevalence of psychoses in pre-pubertal children is relatively rare (Thomsen, 1996), although the incidence of first episode psychosis (FEP) rapidly increases after the age of 15 years (Amminger et al., 2006, Gillberg et al., 1986, Hare et al., 2010), with the highest rate of a first episode between the ages of 15 and 24 years (Amminger et al., 2006, Archie et al., 2007). Young people, aged 12–24 years, represent an important population to study psychotic disorders as such individuals represent a subgroup of patients less likely to be exposed to critical environmental factors such as chronic use of antipsychotic medication (Epstein et al., 2014). There is also evidence that the corpus callosum, the highest order, latest maturing network of the brain, continues to grow until the middle 20's (i.e. 25.45 years) (Pujol et al., 1993). This, as well as synaptic pruning, which continues until the mid-20's, suggests full brain development is incomplete until around 25 years of age (Andersen, 2003). Young people are also at a great risk of substance abuse, particularly those for whom the age of onset of drug use (alcohol and cannabis, in particular) occurs prior to around 15 years of age (Archie et al., 2007, Wells et al., 2009, Palmer et al., 2009). Archie et al. (2007) stratified FEP subjects, between 15 and 50 years, into age ranges and found that those between the ages of 18–24 years accounted for the largest faction (i.e. 45%) of patients engaged in concurrent drug use (Archie et al., 2007). It would appear both psychotic episodes and substance use during a time when the brain has not fully developed could have detrimental effects for patients in the long-term, and cognition and symptomatology during this formidable time needs to be further investigated. Thus, in terms of evaluating the potential cognitive dissimilarities associated with and without concurrent cannabis use in psychotic disorders a focus on young individuals is highly warranted.
Crean et al.’s (2011) extensive review demonstrates the various effects of acute (i.e. 0–6 h after use), residual (7 h–20 days after use), and long-term (at least 21 days since use) effects of cannabis on neuropsychological functions in healthy populations (Crean et al., 2011, Broyd et al., 2016, Curran et al., 2016; Ranganathan and D'Souza, 2006). Acute effects of cannabis tend to show the greatest degree of dysfunction, with subjects demonstrating impairment across attention, decision making, impulsivity and working memory. Both residual and long-term effects appear to largely revert to near-normal functioning, specifically in attention, impulsivity and working memory, with a greater period of abstinence showing the most advanced improvement in cognition. Theoretically, cannabis using patients with a psychotic disorder would be expected to perform worse than their non-using counterparts across several cognitive domains, in keeping with studies in healthy individuals; whereby poorer cognitive performance in those who are either CANN+ or CANN± is most pronounced in tests of executive functioning and processing speed (Meier et al., 2012). In contrast, there is evidence that chronic schizophrenia patients who have a history of cannabis use (CANN±) outperform their CANN- peers (with schizophrenia) in general intelligence, attention, working memory, executive abilities and visuo-spatial abilities (Yücel et al., 2012, Bugra et al., 2013, Jockers-Scherübl et al., 2007, Rabin et al., 2011). Following this logic, one might assume that younger individuals with psychotic disorders (e.g. FEP) who use cannabis, but abstain later, will demonstrate improved cognitive functioning compared to their peers who never used cannabis. Given this, it is possible that the cannabis using patients' psychoses stem from an inherent gene-environment interaction partially owing to their early onset of cannabis use. Such a subgroup of patients may be diagnosed with psychosis, but may also have an atypical neurocognitive profile. This reflects Pearlson's (2015) review examining significant clinical overlap of psychoses and schizophrenia-spectrum disorders (Pearlson, 2015). Furthermore, there is evidence such as that provided by the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study, showing that there are clusters of individuals with shared biological features (known as ‘biotypes’) despite there being a commingling of their traditional clinical phenotype (i.e. schizophrenia or affective psychoses disorders) (Hill et al., 2013, Tamminga et al., 2014). Importantly, one of the three biotypes identified appears to be associated with higher cannabis use, better cognition, and lower percentage of affected relatives (Tamminga et al., 2017). This theory is supported by evidence, which shows that chronic schizophrenia patients with CANN± who first began using cannabis before the age of 17 years exhibit some superior cognitive functioning compared to patients with later (i.e. after 16 years of age) cannabis-use onset (Yücel et al., 2012, Jockers-Scherübl et al., 2007, Hanna et al., 2016).
Yücel et al.s' (2012) meta-analysis investigated the effect of past cannabis use, typically prior to psychosis onset, on neuropsychological performance of older adults (i.e. mean age of patients was above 27 years) with a diagnosis of schizophrenia (Yücel et al., 2012). CANN± outperformed patients with no history of use (CANN-) in tests of global cognition, processing speed, visual memory, planning, and working memory. However, they also found that patients who currently use cannabis (CANN+) did not demonstrate superior cognitive performance across a range of measures. Although, these groups differed significantly in one cognitive domain: the CANN+ showed worse performance in tests of verbal memory. Similarly, a separate study utilized biological radioimmunoassay testing rather than drug-use questionnaires to measure current drug use in schizophrenia patients, and found no significant cognitive differences between current cannabis-using patients and their non-using counterparts (Bahorik et al., 2014). However, there are several factors that may affect cognitive results, including frequency, dosage, and time since last cannabis intake. D'Souza et al. (2005) found evidence of dose-specific effects of THC on the cognition of schizophrenia patients (D'Souza et al., 2005). They demonstrated temporarily increased learning and recall deficits after 2.5 mg or 5 mg of intravenous THC, compared to 0 mg, with patients in the 5 mg group showing a pattern of worse cognitive performance compared to 2.5 mg.
On the surface, a history of moderate, (potentially regular) lifetime use of cannabis followed (importantly) by a period of abstinence in psychosis patients reveals a ‘superior’ cognitive profile compared to those with a psychotic disorder who never used or those who have continued to use (i.e. current use in older, more chronic stages of schizophrenia). Intriguingly, it appears that when cannabis use begins during adolescence, before the age of 17, those who later abstain (i.e. CANN±) demonstrate better neurocognitive performance than their CANN± peers who began using after 17 years. However only a handful of studies report any evidence of cognitive dysfunction in cannabis-using adolescents diagnosed with psychosis. Furthermore, cannabis use in the neurodevelopmental period of adolescence has been shown to confer a range of cognitive, social, and psychological harms (Meier et al., 2012, Tien and Anthony, 1990, Henquet et al., 2004, Szoke et al., 2014, Di Forti et al., 2014, Scholes-Balog et al., 2016, Meier et al., 2015, Mackie et al., 2013). In fact, Henquet et al. (2004) found that any cannabis use exacerbates psychotic symptoms in young people, particularly in those who have a predisposition for psychosis (Henquet et al., 2004).
Given the above-mentioned findings, the aim of the current study was to systematically review the potential effects of cannabis use on cognition in adolescent and young adult patients with psychosis. From previous evidence, we expected cannabis users to show significant deficits across a range of neurocognitive tests, as compared to non-using patients. However, young cannabis-using patients were expected to demonstrate superior neurocognitive performance compared to older CANN+ and CANN-, or young CANN-.
Section snippets
Search strategy and selection criteria
Studies were identified through extensive online database searches, including PubMed, Medline, and Psycinfo. Searches included keywords involving psychosis (i.e. schizophrenia, schizophreniform, psychosis, schizoaffective, schizo*, FEP, first, episode), cannabis (i.e. cannabis, marijuana, THC, tetrahydrocannabinol), and cognition (i.e. neuropsycho*, neurocognit*, cogniti*), and were limited to English-language articles with human participants. All articles up to October 2016 (i.e. the month the
Results
A total of 14 studies, published up to October 2016, met inclusion criteria and were incorporated into the meta-analysis (see Table 2). Six of the studies included patients diagnosed with solely psychotic disorders (Bugra et al., 2013, de la Serna et al., 2010, McCleery et al., 2006, González-Pinto et al., 2016, Núñez et al., 2016, Lev-Ran et al., 2012), while the remaining eight focused on patients diagnosed with narrower schizophrenia-spectrum disorders (Wobrock et al., 2013, Sánchez-Torres
Discussion
To our knowledge, this was the first meta-analysis to systematically investigate the neurocognitive profile of psychotic disorders in young people who use cannabis. As expected, never-using patients (CANN-) outperformed current cannabis-using cases (CANN+) across tests of premorbid and current IQ, verbal learning, verbal working memory, and motor inhibition. This is consistent with previous studies showing that patients with current or recent cannabis use display cognitive deficits when
Role of the funding source
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Contributors
SERB conducted the literature search, data collection, meta-analytic procedures, data analysis, and drafting the manuscript. RSCL was responsible for data analysis and drafting the manuscript. IBH edited the manuscript. DFH was responsible for study design and drafting the manuscript. All authors contributed to, and have approved the final manuscript.
Conflicts of interest
All authors declare that they had no conflicts of interest.
Acknowledgements
We would like to thank authors of Bugra et al., 2013, Coulston et al., 2007, de la Serna et al., 2010, Ferraro et al., 2013, Fischer et al., 2015, González-Pinto et al., 2016, Lev-Ran et al., 2012, McCleery et al., 2006, Núñez et al., 2016, Rabin et al., 2013, Ringen et al., 2010; Sánchez-Torres et al., 2013, Scholes and Martin-Iverson, 2010, Wobrock et al., 2013 for providing additional information about their published studies.
References (144)
Trajectories of brain development: point of vulnerability or window of opportunity?
Neurosci. Biobehav. Rev.
(2003)- et al.
Neurocognitive and social cognitive predictors of cannabis use in first-episode psychosis
Schizophr. Res.
(2015) - et al.
Impairment of inhibitory control processing related to acute psychotomimetic effects of cannabis
Eur. Neuropsychopharmacol.
(2015) - et al.
Neural basis of Delta-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition
Biol. Psychiatr.
(2008) - et al.
Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia
Prog. Neurobiol. (N. Y.)
(2010) - et al.
Cannabis abuse is associated with better emotional memory in schizophrenia: a functional magnetic resonance imaging study
Psychiatr. Res.
(2013) - et al.
Acute and chronic effects of cannabinoids on human cognition - a systematic review
Biol. Psychiatr.
(2016) - et al.
Evaluating the relationship between cannabis use and IQ in youth and young adults at clinical high risk of psychosis
Psychiatr. Res.
(2015) - et al.
Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction
Biol. Psychiatr.
(2005) - et al.
The neuropsychological correlates of cannabis use in schizophrenia: lifetime abuse/dependence, frequency of use, and recency of use
Schizophr. Res.
(2007)
Cannabis use, cognition and brain structure in first-episode psychosis
Schizophr. Res.
Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction
Biol. Psychiatr
Studies on [3H]CP-55940 Binding in the human central nervous system: regional specific changes in density of Cannabinoid-1 receptors associated with schizophrenia and cannabis use
Neuroscience
Neurocognitive impairment in middle-aged and older adults with bipolar disorder: comparison to schizophrenia and normal comparison subjects
J. Affect. Disord.
Cannabis use disorders in schizophrenia: effects on cognition and symptoms
Schizophr. Res.
Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes
Schizophr. Res.
Acute and residual effects of marijuana in humans
Pharmacol. Biochem. Behav.
Cannabis users have higher premorbid IQ than other patients with first onset psychosis
Schizophr. Res.
Risk-taking in schizophrenia and controls with and without cannabis dependence
Schizophr. Res.
Spatial working memory performance in patients with schizoaffective psychosis versus schizophrenia: a tale of two disorders?
Schizophr. Res.
Cannabis use and outcome of recent onset psychosis
Eur. Psychiatr.
Are schizophrenia and schizoaffective disorder neuropsychologically distinguishable?
Schizophr. Res.
Acute and residual effects of marijuana: profiles of plasma THC levels, physiological, subjective, and performance measures
Pharmacol. Biochem. Behav.
Cognitive changes in patients with acute phase psychosis—effects of illicit drug use
Psychiatr. Res.
Different psychological effects of cannabis use in adolescents at genetic high risk for schizophrenia and with attention deficit/hyperactivity disorder (ADHD)
Schizophr. Res.
Cannabis induces different cognitive changes in schizophrenic patients and in healthy controls
Prog. Neuro-Psychopharmacol. Biol. Psychiatry
Drug abuse and/or dependence and better neuropsychological performance in patients with schizophrenia
Schizophr. Res.
Cognitive functioning in patients with schizophrenia and bipolar disorder: a quantitative review
Schizophr. Res.
Substance abuse in first-episode non-affective psychosis
Schizophr. Res.
A meta-analysis of cognitive deficits in first-episode Major Depressive Disorder
J. Affect. Disord.
Neurocognitive functions of heavy cannabis using schizophrenia patients
Eur. Psychiatr.
Substance misuse and cognitive functioning in early psychosis: a 2 year follow-up
Schizophr. Res.
Associations of adolescent cannabis use with academic performance and mental health: a longitudinal study of upper middle class youth
Drug Alcohol Depend.
Neuropsychological assessment of memory in child and adolescent first episode psychosis: cannabis and <<the paradox effect>>
Rev. Psiquiatía Salud Ment.
Developmental epidemiology of drug use and abuse in adolescence and young adulthood: evidence of generalized risk
Drug Alcohol Depend.
Catechol-O-Methyltransferase (COMT) Val158Met variations and cannabis use in first-episode non-affective psychosis: clinical-onset implications
Psychiatr. Res.
CANTAB explicit memory is less impaired in addicted schizophrenia patients
Brain Cognit.
Contradictory cognitive capacities among substance-abusing patients with schizophrenia: a meta-analysis
Schizophr. Res.
No additive effect of cannabis on cognition in schizophrenia
Schizophr. Res.
Treated incidence of first-episode psychosis in the catchment area of EPPIC between 1997 and 2000
Acta Psychiatr. Scand.
Substance use and abuse in first-episode psychosis: prevalence before and after early intervention
Schizophr. Bull.
Adolescent initiation of cannabis use and early-onset psychosis
Subst. Abuse
Neurocognitive functioning of individuals with schizophrenia: using and not using drugs
Schizophr. Bull.
Neuropsychological abnormalities in schizophrenia and major mood disorders: similarities and differences
Curr. Psychiatry Rep.
Neuroimaging studies of acute effects of THC and CBD in humans and animals: a systematic review
Curr. Pharmaceut. Des.
The neural basis for the acute effects of cannabis on learning and psychosis
Cognitive functioning in schizophrenia, schizoaffective disorder and affective psychoses: meta-analytic study
Br. J. Pharmacol.
Cannabis use and cognitive functions in at-risk mental state and first episode psychosis
Psychopharmacology
Pathways from cannabis to psychosis: a review of the evidence
Front. Psychiatr.
Cited by (25)
Does cannabis affect cognitive functioning in patients with schizophrenia?
2024, Schizophrenia Research: CognitionCross-sectional and longitudinal assessment of the association between DDR1 variants and processing speed in patients with early psychosis and healthy controls
2023, Journal of Psychiatric ResearchCitation Excerpt :However, this hypothesis is not confirmed with the results from our longitudinal data where we did not find an interaction between time and the risk genotype. Several differential disease features between EP and SZ may also explain these results: (1) the highest prevalence of negative symptoms in SZ (Correll and Schooler, 2020) which is negatively associated with PS (Harvey et al., 2006; Rodríguez-Sánchez et al., 2008); (2) EP includes patients who do not develop SZ and that probably have high cognitive functioning scores (Vaskinn et al., 2020); (3) cannabis use in EP is more frequent and may influence PS (Bogaty et al., 2018); and (4) there are drug treatment differences between EP and SZ (Tsutsumi et al., 2011). For instance in the Santander sample, patients released from the early intervention psychosis program had higher antipsychotic doses (Ayesa-Arriola et al., 2021).
The blind men and the elephant: Systematic review of systematic reviews of cannabis use related health harms
2020, European NeuropsychopharmacologyCitation Excerpt :There is enough evidence to endorse the claim of a negative impact of cannabis use on cognition, even after the person is no longer acutely intoxicated (“stoned”) by cannabis use. Memory is the most consistently impaired cognitive domain (g = -0.761 CI95% −1.30 to −0.22) (Bogaty et al., 2018). Moreover, cannabis use leads to cognitive adverse effects on multiple aspects of cognition.
The prevalence and clinical correlates of cannabis use and cannabis use disorder among patients with bipolar disorder: A systematic review with meta-analysis and meta-regression
2019, Neuroscience and Biobehavioral ReviewsCitation Excerpt :A recent meta-analysis showed that the prevalence of CUD among patients with schizophrenia was 26.2% in clinical settings, similar to our result (Hunt et al., 2018). Other meta-analyses have shown poor outcomes associated with the comorbidity of psychotic disorder with cannabis use, e.g., neurocognition deficits (Bogaty et al., 2018), the severity of clinical symptoms, and worse social function (Large et al., 2014). The prevalence of CUD among patients with major depressive disorder has been shown to be lower than that found in bipolar disorder and schizophrenia (Patten et al., 2015).
Age of onset of Cannabis use and cognitive function in first-episode non-affective psychosis patients: Outcome at three-year follow-up
2018, Schizophrenia ResearchCitation Excerpt :In this vein, literature based on adolescents with psychotic disorder showed better outcome in the groups of cannabis users than non-users (Kumra et al., 2005; de la Serna et al., 2010). However, contrary to the previous cited studies, a recent meta-analysis (Bogaty et al., 2018) focused in young patients with psychosis found that cannabis users had worse cognitive performance. We observed that, there is a lack of knowledge about how different cognitive domains evolve in FEP patients who consume cannabis when taking into account the age at which they began their use.
Introduction to JINS Special Issue: Clarifying the Complexities of Cannabis and Cognition
2021, Journal of the International Neuropsychological Society